These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28641336)

  • 1. Suppression of Forkhead Box Protein O1 (FOXO1) Transcription Factor May Promote Adrenocortical Tumorigenesis.
    Stenman A; Murtha T; Korah R; Carling T
    Horm Metab Res; 2017 Aug; 49(8):631-637. PubMed ID: 28641336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
    Cheng JY; Brown TC; Murtha TD; Stenman A; Juhlin CC; Larsson C; Healy JM; Prasad ML; Knoefel WT; Krieg A; Scholl UI; Korah R; Carling T
    BMC Cancer; 2017 Mar; 17(1):164. PubMed ID: 28249601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
    Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
    Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
    Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
    Blanes A; Diaz-Cano SJ
    Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
    Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
    Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
    De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC; Nicolson NG; Korah R; Carling T
    J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.
    Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B
    Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.
    Aronova A; Min IM; Crowley MJP; Panjwani SJ; Finnerty BM; Scognamiglio T; Liu YF; Whitsett TG; Garg S; Demeure MJ; Elemento O; Zarnegar R; Fahey TJ
    Ann Surg Oncol; 2018 Mar; 25(3):792-800. PubMed ID: 29214451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
    Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior.
    Brown TC; Murtha TD; Rubinstein JC; Korah R; Carling T
    Cell Commun Signal; 2018 Jun; 16(1):27. PubMed ID: 29884238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Nrf2 expression and mutation with Weiss and Helsinki scores in adrenocortical carcinoma.
    Kamai T; Murakami S; Arai K; Ishida K; Kijima T
    Cancer Sci; 2022 Jul; 113(7):2368-2377. PubMed ID: 35467062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.
    Pereira SS; Máximo V; Coelho R; Batista R; Soares P; Guerreiro SG; Sobrinho-Simões M; Monteiro MP; Pignatelli D
    J Cell Biochem; 2017 Aug; 118(8):2064-2071. PubMed ID: 27886397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?
    Bulzico D; Faria PAS; Maia CB; de Paula MP; Torres DC; Ferreira GM; Pires BRB; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
    Endocrine; 2017 Nov; 58(2):276-288. PubMed ID: 28887601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA HOTAIR participates in the development and progression of adrenocortical carcinoma via regulating cell cycle.
    Yan ZC; He L; Qiu JH; Deng WT; Lu JR; Yuan Z; Liu DJ; Zheng RQ; Jiang W
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6640-6649. PubMed ID: 30402836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.